Prostate cancer is the most common newly diagnosed cancer in men. An estimated 164,690 new cases of prostate cancer will be diagnosed in 2018 (1). Radiation therapy is a common treatment for prostate cancer with up to 41% of patients receiving this treatment depending on disease stage. Prostate cancer has a high 5-year survival rate at 98.9%, however the estimated 29,430 deaths from prostate cancer represent about 9% of all cancer deaths in men. In addition, many prostate cancer survivors who have been treated with radiation therapy experience incontinence, erectile dysfunction, and bowel complications. In all, these complications can affect more than 50% of the prostate cancer patients treated with radiation. Therefore, the quality of life for patients may greatly increase from a therapy to prevent these radiation side effects.
BIO 300 is being evaluated to prevent the incidence of erectile dysfunction (ED) associated with radiation of the prostate. In nonclinical studies, BIO 300 protected normal prostate tissue from radiation related toxicities. Penile blood flow and sexual function levels were maintained following prostate directed radiation in experimental groups treated with BIO 300.
In addition, BIO 300’s ability to increase tumor growth delay has been investigated using both human androgen-independent and androgen-dependent prostate cancer cell lines in a xenograft models treated with or without radiation therapy. BIO 300 alone and in combination with radiation treatment, both significantly increases tumor growth delay compared to the respective controls. Importantly, BIO 300 had a therapeutic benefit on both androgen-independent and androgen-dependent tumor growth in the absence of radiation.
- American Cancer Society. Cancer Facts & Figures 2018. Atlanta: American Cancer Society, 2018.